The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Lara Rodriguez Sanchez, Samir Taneja, Hashim Ahmed, Himanshu Nagar, Edward Schaeffer in a Crossfire: Controversies in Urology debate: discussed if Focal Therapy is a Suitable Option for all Cases with ...

AUA annual meeting featured a kidney cancer session and a presentation by Dr. Pratik Kanabur discussing a cost-effectiveness analysis of 89 Zr-girentuximab PET-CT (TLX250) to guide management of small ...

AUA annual meeting featured a prostate cancer session and a presentation by Dr. Madison Krischak discussing access to prostate cancer clinical trials in the VA and whether veterans with prostate ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the Plenary Session on Saturday. Dr. Samir Taneja gave the State-of-the-Art Lecture titled: ...

Many patients with prostate cancer rely on caregivers to provide emotional and physical support and help with navigating challenges surrounding medical management. A quantitative survey was conducted ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...

Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic variants throughout ...

Peyronie's disease (PD) is a well-known penile condition that primarily affects adult males. Patients with PD typically present with a palpable nodule in the penis. However, there has now been ...

Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for ...

Andrea Miyahira: Hi, everyone, I'm Andrea Miyahira with the Prostate Cancer Foundation. I'm happy to be joined by Dr. Nada Lallous at the University of British Columbia. She will discuss her paper, AR ...

The aim of this study was to evaluate the prognostic value of undetectable circulating tumor DNA (ctDNA) and the dose-response relationship between ctDNA levels and survival outcomes in metastatic ...